Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice.
Emerging evidence suggests that transforming growth factor-beta (TGF-beta) is an important mediator of diabetic nephropathy. We showed previously that short-term treatment with a neutralizing monoclonal anti-TGF-beta antibody (alphaT) in streptozotocin-diabetic mice prevents early changes of renal hypertrophy and increased matrix mRNA. To establish that overactivity of the renal TGF-beta system mediates the functional and structural changes of the more advanced stages of nephropathy, we tested whether chronic administration of alphaT prevents renal insufficiency and glomerulosclerosis in the db/db mouse, a model of type 2 diabetes that develops overt nephropathy. Diabetic db/db mice and nondiabetic db/m littermates were treated intraperitoneally with alphaT or control IgG, 300 microgram three times per week for 8 wk. Treatment with alphaT, but not with IgG, significantly decreased the plasma TGF-beta1 concentration without decreasing the plasma glucose concentration. The IgG-treated db/db mice developed albuminuria, renal insufficiency, and glomerular mesangial matrix expansion associated with increased renal mRNAs encoding alpha1(IV) collagen and fibronectin. On the other hand, treatment with alphaT completely prevented the increase in plasma creatinine concentration, the decrease in urinary creatinine clearance, and the expansion of mesangial matrix in db/db mice. The increase in renal matrix mRNAs was substantially attenuated, but the excretion of urinary albumin factored for creatinine clearance was not significantly affected by alphaT treatment. We conclude that chronic inhibition of the biologic actions of TGF-beta with a neutralizing monoclonal antibody in db/db mice prevents the glomerulosclerosis and renal insufficiency resulting from type 2 diabetes.
Ziyadeh
F N
FN
Renal-Electrolyte and Hypertension Division, University of Pennsylvania, Philadelphia, PA 19104-6144, USA. ziyadeh@mail.med.upenn.edu
Hoffman
B B
BB
Han
D C
DC
Iglesias-De La Cruz
M C
MC
Hong
S W
SW
Isono
M
M
Chen
S
S
McGowan
T A
TA
Sharma
K
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000235:genetics; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000187:drug effects*; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis; D005920:Glomerular Mesangium / Q000187:drug effects* / Q000473:pathology; D051379:Mice; D008817:Mice, Mutant Strains; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II; D011956:Receptors, Cell Surface; D054411:Receptors, Leptin; D018125:Receptors, Transforming Growth Factor beta / Q000096:biosynthesis; D051437:Renal Insufficiency / Q000209:etiology / Q000517:prevention & control*; D016212:Transforming Growth Factor beta / Q000276:immunology*; D015854:Up-Regulation
D000911:Antibodies, Monoclonal; D002352:Carrier Proteins; D016326:Extracellular Matrix Proteins; D011956:Receptors, Cell Surface; D054411:Receptors, Leptin; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II